ABSTRACT
BACKGROUND: First-line therapy does not always provide a high level of Helicobacter pylori eradication due to the increase of H. pylori resistance to antibiotics; therefore, it remains necessary to identify the most effective rescue treatments. The purpose of this study was to evaluate the efficacy and safety of empirical H. pylori furazolidone-containing regimens. MATERIALS AND METHODS: Adult H. pylori infected patients empirically treated with furazolidone-containing eradication regimens were registered in an international, prospective, multicenter non-intervention European registry on H. pylori management (Hp-EuReg). Data were collected at AEG-REDCap e-CRF from 2013 to 2021 and the quality was reviewed. Modified intention-to-treat (mITT) effectiveness analyses were performed. RESULTS: Overall 106 patients received empirical furazolidone-containing therapy in Russia. Furazolidone was prescribed in a sequential scheme along with amoxicillin, clarithromycin and a proton pump inhibitor in 68 (64%) cases, triple regimens were prescribed in 28 (26%) patients and quadruple regimens in 10 (9.4%). Treatment duration of 7 days was assigned to 2 (1.9%) patients, 10-day eradication therapy in case of 80 (75%) and 14 days - in 24 (23%) patients. Furazolidone was mainly used in first- (79%) and second-line (21%) regimens. The methods used to diagnose H. pylori infection were: histology (81%), stool antigen test (64%), 13C-urea breath test (6.6%), and rapid urease test (1.9%). The mITT effectiveness of sequential therapy was 100%; 93% with the triple therapy and 75.5% with quadruple therapy. Compliance was reported in 98% of cases. Adverse events were revealed in 5.7% of patients, mostly nausea (3.8%). No serious adverse events were reported. CONCLUSION: Furazolidone containing eradication regimens appear to be an effective and safe empirical therapy in Russia.
Subject(s)
Helicobacter Infections , Helicobacter pylori , Adult , Humans , Furazolidone/adverse effects , Prospective Studies , Drug Therapy, Combination , Anti-Bacterial Agents/adverse effects , Amoxicillin/adverse effects , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Helicobacter Infections/diagnosis , Proton Pump Inhibitors/adverse effects , Treatment Outcome , Russia/epidemiology , RegistriesSubject(s)
Anti-Bacterial Agents/administration & dosage , Clarithromycin/administration & dosage , Drug Resistance, Bacterial , Helicobacter Infections , Helicobacter pylori , Stomach Ulcer , Female , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Humans , Male , Russia/epidemiology , Stomach Ulcer/drug therapy , Stomach Ulcer/epidemiology , Stomach Ulcer/microbiology , Urban PopulationSubject(s)
Benzimidazoles/economics , Benzimidazoles/therapeutic use , Gastroesophageal Reflux/drug therapy , Gastroesophageal Reflux/economics , Proton Pump Inhibitors , Proton Pumps/economics , 2-Pyridinylmethylsulfinylbenzimidazoles , Administration, Oral , Adult , Aged , Drug Administration Schedule , Female , Humans , Male , Middle Aged , Omeprazole/analogs & derivatives , Rabeprazole , Treatment OutcomeSubject(s)
Pancreatitis/drug therapy , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Benzimidazoles/therapeutic use , Chronic Disease , Double-Blind Method , Drug Therapy, Combination , Enzyme Inhibitors/therapeutic use , Female , Humans , Male , Middle Aged , Omeprazole/therapeutic use , Pilot Projects , Proton-Translocating ATPases/antagonists & inhibitors , Rabeprazole , RussiaABSTRACT
The criteria of choice of proton pump inhibitor at acid-dependent diseases such as gastroesophageal reflux, peptic ulcer, diseases associated with Helicobacter pylory are discussed in the article. The presented data of meta-analysis of efficiency (clinical-and-endoscopic, economical), safety and tolerance, cost and simplicity of use show that today rabeprasol (pariet) is the drug of choice.
Subject(s)
Anti-Ulcer Agents/therapeutic use , Gastroesophageal Reflux/drug therapy , Proton Pump Inhibitors , Anti-Ulcer Agents/pharmacology , HumansSubject(s)
Duodenal Ulcer/drug therapy , Helicobacter Infections/drug therapy , Helicobacter pylori , 2-Pyridinylmethylsulfinylbenzimidazoles , Adolescent , Adult , Amoxicillin/administration & dosage , Amoxicillin/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/administration & dosage , Anti-Ulcer Agents/therapeutic use , Benzimidazoles/administration & dosage , Benzimidazoles/therapeutic use , Clarithromycin/administration & dosage , Clarithromycin/therapeutic use , Drug Therapy, Combination , Duodenal Ulcer/microbiology , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/therapeutic use , Female , Humans , Male , Middle Aged , Omeprazole/administration & dosage , Omeprazole/analogs & derivatives , Omeprazole/therapeutic use , Penicillins/administration & dosage , Penicillins/therapeutic use , Proton-Translocating ATPases/antagonists & inhibitors , RabeprazoleABSTRACT
AIM: Choice of optimal antihelicobacter (AH) treatment of ulcer. MATERIALS AND METHODS: 249 outpatients with duodenal ulcer associated with Helicobacter pylori entered a blind multicenter controlled trial. The patients were given one of the following drugs: metronidazole, tonidazol, amoxicilline, clarithromycin, rovamycin, omeprazole, azitromycin. RESULTS: Of all the drugs used, rovamycin appeared preferable as it has high AH activity, is safe and cost-effective. CONCLUSION: Rovamycin has a high AH activity and can be applied for treatment of diseases associated with Helicobacter pylori as a drug of choice.